Motapizone

Cat. No.:	HY-106739
CAS No.:	90697-57-7
Molecular Formula:	$C_{12}H_{12}N_4OS$
Molecular Weight:	260.31
Target:	Phosphodiesterase (PDE)
Pathway:	Metabolic Enzyme/Protease
Storage:	Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month



BIOLOGICAL ACTIVITY

Description	Motapizone (NAT 05-239) is a selective PDE3 inhibitor. Motapizone moderately inhibits cytokine release in lipopolysaccharide (LPS)-induced alveolar macrophages. Motapizone also inhibits human platelet aggregation by increasing intracellular cAMP[1][2].
IC_{50} & Target	PDE3
In Vitro	Motapizone (10 μM; 15 min before oxidants) results 20% inhibition rate for cytokine release in lipopolysaccharide (LPS)-induced alveolar macrophages with oxidative stress conditions, but the inhibitory effect is not affected by oxidative stress[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Milara J, et al. Oxidative stress-induced glucocorticoid resistance is prevented by dual PDE3/PDE4 inhibition in human alveolar macrophages. Clin Exp Allergy. 2011 Apr;41(4):535-46.

[2]. Borbe HO, et al. Inhibition of human platelet aggregation by motapizone via an increase in intracellular cAMP. Agents Actions Suppl. 1986;20:249-57.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA